{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:00:00Z","timestamp":1781715600795,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T00:00:00Z","timestamp":1181001600000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust NZ J Obst Gynaeco"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:\u2002<\/jats:bold> Oxycodone has become popular for post\u2010Caesarean section (CS) analgesia yet it is not currently recommended for use in breast\u2010feeding mothers because of limited information on its excretion into breast milk.<\/jats:p><jats:p><jats:bold>Aim:\u2002<\/jats:bold> To investigate the relationship between maternal ingestion of oxycodone after CS and the resultant maternal plasma, breast milk and neonatal plasma drug levels up to 72\u2010h post\u2010partum.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Fifty breast\u2010feeding mothers taking oxycodone had blood and breast milk samples analysed for oxycodone levels at 24\u00a0h intervals after CS. Forty\u2010one neonates had blood samples taken at 48\u00a0h.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Oxycodone was detected in the milk of mothers who had taken any dose in a 24\u2010h period, with significant correlation between maternal plasma and milk levels (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00.81). The median milk:plasma (M:P) ratio for the same period was 3.2:1. Over the subsequent 48\u00a0h, the relationship between plasma and milk levels was less strong (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00.59) and there was a larger range of M:P levels with evidence of persistence of oxycodone in the breast milk of some mothers. Oxycodone levels up to 168\u00a0ng\/mL were detected in breast milk (20%\u00a0&gt;\u00a0100\u00a0ng\/mL). Oxycodone was detected in the plasma of one infant.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Oxycodone is concentrated in human breast milk up to 72\u2010h post\u2010partum. Breastfed infants may receive &gt; 10% of a therapeutic infant dose. However, maternal oxycodone intake up to 72\u2010h post\u2010CS poses only minimal risk to the breast\u2010feeding infant as low volumes of breast milk are ingested during this period.<\/jats:p>","DOI":"10.1111\/j.1479-828x.2007.00715.x","type":"journal-article","created":{"date-parts":[[2007,6,6]],"date-time":"2007-06-06T02:05:58Z","timestamp":1181095558000},"page":"181-185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Oxycodone as a component of multimodal analgesia for lactating mothers after Caesarean section: Relationships between maternal plasma, breast milk and neonatal plasma levels"],"prefix":"10.1111","volume":"47","author":[{"given":"Suzette","family":"SEATON","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"REEVES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McLEAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-5223.1976.tb01197.x"},{"key":"e_1_2_6_3_2","unstructured":"Mundipharma.Product information approved by the Therapeutic Goods Administration: Oxynorm. Australia 17\/4\/2002."},{"key":"e_1_2_6_4_2","unstructured":"Mundipharma.Product information approved by the Therapeutic Goods Administration: Oxycontin. Australia 1\/4\/2005."},{"key":"e_1_2_6_5_2","unstructured":"Sigma.Product information approved by the Therapeutic Goods Administration: Endone. Australia 1\/11\/1996."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2006.02.025"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200002030-00006"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200007133430208"},{"key":"e_1_2_6_9_2","unstructured":"Micromedex.Drugdex Drug Evaluation \u2013 Oxycodone. Health Communication Network 2006. [Accessed 10 October 2006.]Available fromhttp:\/\/micromedex.hcn.net.au."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/089033449501100123"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2005.01571.x"},{"key":"e_1_2_6_12_2","unstructured":"Mundipharma.Product information approved by the Therapeutic Goods Administration: Oxynorm. Australia 09\/05\/2005."},{"key":"e_1_2_6_13_2","first-page":"474","article-title":"Oxycodone excretion in human milk in the puerperium [Abstract]","volume":"20","author":"Marx CM","year":"1986","journal-title":"Drug Intell Clin Pharm"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1994.tb01068.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198814040-00003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528050-00004"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.10.035"},{"key":"e_1_2_6_18_2","first-page":"119","article-title":"Medications in the breast\u2010feeding mother","volume":"64","author":"Spencer JP","year":"2001","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5245(03)00217-7"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330370053031"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/fn.88.5.F380"},{"key":"e_1_2_6_22_2","volume-title":"Paediatric Pharmacopoeia Royal Children's Hospital","author":"Kemp CA","year":"2002"}],"container-title":["Australian and New Zealand Journal of Obstetrics and Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1479-828X.2007.00715.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1479-828X.2007.00715.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T04:27:05Z","timestamp":1697084825000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1479-828X.2007.00715.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1111\/j.1479-828X.2007.00715.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1479-828x.2007.00715.x","archive":["Portico"],"relation":{},"ISSN":["0004-8666","1479-828X"],"issn-type":[{"value":"0004-8666","type":"print"},{"value":"1479-828X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"2007-06-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}